Loading clinical trials...

Topical Application of AS101 for the Treatment of Psoriasis | Clinical Trials | Clareo Health

WITHDRAWNPhase 2NCT00788424

Topical Application of AS101 for the Treatment of Psoriasis

This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.

Lead sponsor: BioMAS Ltd•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 1

A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

NCT05965089 · Healthy Volunteers, Mild to Moderate Psoriasis

UNKNOWNPhase 3

A Phase III Study in Subjects With Mild to Moderate Psoriasis.

NCT05249972 · Mild to Moderate Psoriasis

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 23, 2015Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE2

Enrollment—

Start dateNov 2008

Last updatedJul 23, 2015

Condition

Mild to Moderate Psoriasis

Locations shown

Hadassah Medical Organization

Jerusalem

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 23, 2015Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions